Robin Swartz, Chief Operating Officer of Voyager Therapeutics (NASDAQ: VYGR), sold 6,458 shares of common stock on February 24, 2026, according to a Form 4 filing with the Securities and Exchange Commission.
The shares were sold at prices between $3.61 and $3.86, producing proceeds of approximately $24,346. The filing states the shares were relinquished to cover tax withholding obligations that arose from the vesting of restricted stock units on February 21, 2026.
The transaction was executed under a pre-existing automatic sale instruction that Swartz adopted on May 12, 2025. The Form 4 filing specifies that the disposition was not a discretionary trade by Swartz but part of that pre-arranged mechanism. After the sale, Swartz directly holds 199,738 shares of Voyager Therapeutics common stock.
The sale comes amid notable recent price moves for the stock. Over the prior week the share price increased nearly 20%, and at the time of the filing the stock was trading at $4.18. The sale prices reported in the Form 4 fall below that intraday quote.
Separately, company financial metrics cited in InvestingPro analysis indicate Voyager Therapeutics carries a current ratio of 6.19 and holds more cash than debt. That same InvestingPro assessment characterizes the stock as appearing undervalued according to its Fair Value analysis.
Summary of the key transaction details:
- Insider: Robin Swartz, COO of Voyager Therapeutics
- Shares sold: 6,458
- Sale date: February 24, 2026
- Price range: $3.61 - $3.86
- Proceeds: Approximately $24,346
- Reason: Tax withholding for RSU vesting on February 21, 2026
- Mechanism: Pre-arranged automatic sale instruction adopted May 12, 2025
- Post-transaction direct holdings: 199,738 shares
Investors and market participants interested in more in-depth analysis can consult detailed Pro Research Reports and InvestingPro assessments referenced in the filing and related commentary.